Pharmacy Is Right For Me

SEPTEMBER 24, 2024

Hi Future Pharmacists! My name is Tazche Turner and I am a fourth year PharmD Candidate at the University of North Carolina’s (UNC) Eshelman School of Pharmacy. My passions for science, business and service led me to pursue a career in pharmacy. Throughout pharmacy school, I immersed myself into numerous organizations and leadership positions to really explore all pharmacy has to offer, but the organization I found my pharmacy home in was the Student National Pharmaceutical Association (SNPhA).

Immunization 130

Immunization 130

Pharmacy Times

SEPTEMBER 24, 2024

The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

131

131

STAT

SEPTEMBER 24, 2024

Many disabled people are not included in official U.S. data. This is because there is “ No Box to Check ” to indicate their particular disability on surveys from the U.S. Census Bureau and other federal agencies. The questions used to identify people with disabilities are missing millions. Two question sets are most often used to assess disability in U.S. federal surveys: the American Community Survey Six (ACS-6) or the Washington Group Short Set (WG-SS).

137

137

Drug Topics

SEPTEMBER 24, 2024

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the role his company plays in the ongoing issue of rising drug prices.

112

112

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 24, 2024

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies. Novo has been blaming pharmacy benefit managers for the high list prices of its drugs, arguing that it needs to be able to pay rebates to the middlemen i

135

135

Fierce Healthcare

SEPTEMBER 24, 2024

Pomelo Care, a value-based virtual provider of maternity care, has acquired the Doula Network, now offering virtual and in-person maternity care. | The acquisition expands the company’s reach to more than 15 million covered lives, including more than 1 in 6 Medicaid beneficiaries nationally.

132

132

STAT

SEPTEMBER 24, 2024

STAT is co-publishing this article by Tradeoffs. Lisa Ann Trainor struggled to stay on top of schoolwork, hold a job or even perform basic tasks like laundry for six exhausting years. Then, in 2018, she finally found a drug that kept her ADHD in check.

127

127

Pharmacy Times

SEPTEMBER 24, 2024

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

Vaccines 139

Vaccines 139

STAT

SEPTEMBER 24, 2024

Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past. In an internal memo obtained by STAT, Sanofi said Monday that it has named Mike Quigley, formerly the CEO of startups Dualitas Therapeutics and Therini Bio and senior vice president of research biology at Gilead, as its chief scientific officer and global head of research.

123

123

Fierce Pharma

SEPTEMBER 24, 2024

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain. | Vertex has inked a long-term supply agreement with Swiss CDMO Lonza to crank out global commercial supply of Casgevy. Under the deal, Lonza will produce Casgevy from its cell therapy manufacturing facilities in Geleen in the Netherlands and, eventually, its plant in Portsmouth, New Hampshire.

118

118

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

SEPTEMBER 24, 2024

Generate:Biomedicines, a Flagship Pioneering company using artificial intelligence to create new medicines, announced today that it has struck a deal with Novartis to develop an undisclosed number of targets in various disease areas. With milestone payments, the company is eligible to receive over $1 billion, in addition to royalties. Novartis is paying Generate $65 million up front, which includes $15 million for an undisclosed amount of equity in the company.

122

122

pharmaphorum

SEPTEMBER 24, 2024

After various twists and turns in the regulator path, Ipsen has secured EU approval for Kayfanda, its treatment for severe itching (pruritus) in patients with the rare liver disease Alagille syndrome (ALGS).Kayfanda (odevixibat) is labeled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow – in children aged six months and over with ALGS, a disease caused by a genetic mutation that leads to liver damage and jaundice.

Labelling 118

Labelling 118

Fierce Healthcare

SEPTEMBER 24, 2024

HHS OIG released an analysis of recent RPM claims data, flagging evidence of gaps in CMS oversight. Stakeholders say the report is hyperbolic.

130

130

STAT

SEPTEMBER 24, 2024

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.  The judge overseeing a patent infringement case denied Regeneron’s request for a temporary injunction that would have barred Amgen from immediately selling its Eylea copy, called Pavblu.

111

111

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

SEPTEMBER 24, 2024

The feds have set new deadlines for compliance with Medicaid renewal requirements given widespread enrollment concerns during the unwinding. | The feds have set new deadlines for compliance with Medicaid renewal requirements given widespread enrollment concerns during the unwinding.

111

111

STAT

SEPTEMBER 24, 2024

What was that mosquito thinking as the six needles of its proboscis mouth bit into my mother’s skin? Had it taken a long, unplanned journey in a bag as a tourist traveled north from a tropical Caribbean island? Or was it an old-time New York mosquito that had feasted the night before on the sweaty skin of a feverish traveler from the south? My mother would remain incredulous at her bad luck: Why did this mosquito choose her arm to snack upon?

110

110

Pharmacy Times

SEPTEMBER 24, 2024

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

145

145

STAT

SEPTEMBER 24, 2024

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies did not clearly beat existing competitors on the market. In the Phase 3 trials, dubbed Horizon and Mint, the California company tested therapies for eczema and myasthenia gravis, respectively.

Immunization 110

Immunization 110

Fierce Pharma

SEPTEMBER 24, 2024

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices, prepared remarks from Novo CEO Lars Fruergaard Jørgensen shine a light on the larger U.S. healthcare system.

107

107

STAT

SEPTEMBER 24, 2024

This summer, the American Red Cross declared an emergency blood shortage in the U.S. There’s a seasonal pattern to blood donations, which often dip over the summer and during the winter holidays. But experts also say that climate change disrupts the national blood supply, with extreme heat and worsening storms in certain regions keeping people away from blood banks.

108

108

Outsourcing Pharma

SEPTEMBER 24, 2024

The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for the treatment of the rare disease Niemann-Pick disease type C (NPC), which until now has lacked FDA-approved therapies.

FDA 105

FDA 105

Drug Topics

SEPTEMBER 24, 2024

In the US, Ozempic costs more than 9 times what it does in Germany, while Wegovy is more than 4.5 times more expensive than in Denmark.

98

98

STAT

SEPTEMBER 24, 2024

Gene therapy company Bluebird Bio on Tuesday announced a 25% reduction of its workforce as part of a restructuring meant to save the money as it seeks to market its expensive but potentially life-saving treatments for sickle cell disease and other disorders. The company, which has secured approval from the U.S. Food and Drug Administration for treatments including the sickle-cell gene therapy Lyfgenia, has not yet seen the financial payoff from its scientific breakthroughs — and it says i

104

104

Pharmaceutical Technology

SEPTEMBER 24, 2024

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

120

120

STAT

SEPTEMBER 24, 2024

In the latest slap at a pharmaceutical company by a local government, the city of Baltimore has filed a lawsuit accusing Biogen of striking an “unlawful” scheme with the largest pharmacy benefit managers to block generic competition of a best-selling multiple sclerosis treatment. The effort allegedly originated as Biogen planned to fend off generic companies that hoped to sell lower-cost alternatives to Tecfidera which, several years ago, had been a franchise product and generated

Pharmaceutical Companies 100

Pharmaceutical Companies Pharmaceutical Companies 100

Fierce Pharma

SEPTEMBER 24, 2024

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%. | After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%, or nearly 100 employees.

96

96

pharmaphorum

SEPTEMBER 24, 2024

Roche launches 12 in one test for respiratory virus, using its 'revolutionary' TAGS tech, that can be used in regular clinical labs

109

109

Outsourcing Pharma

SEPTEMBER 24, 2024

The US biotechâs neurological drug candidate showed a reduction in disease progression of at least 50% and the company will now file with the FDA.

FDA 105

FDA 105

pharmaphorum

SEPTEMBER 24, 2024

Discover how the Within3 Insights Management Platform can support smart decision-making with its innovative features and capabilities. Learn more about this powerful solution spotlight.

95

95

Fierce Pharma

SEPTEMBER 24, 2024

Flush with new business, Philadelphia-based CDMO PCI Pharma Services is blueprinting multiple manufacturing outlays on both sides of the Atlantic. | PCI has “heavily invested” in new drug delivery tech at its Philadelphia headquarters, laid plans for a 545,000-square-foot expansion in Rockford, Illinois, acquired a new packaging and device assembly plant near Dublin, Ireland, and broken ground on another at its CityNorth Dublin campus.

Packaging 92

Packaging 92

pharmaphorum

SEPTEMBER 24, 2024

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.Data from the PHOENYCS GO study in moderate to severe SLE patients isn't available yet, but the partners say dapirolizumab pegol achieved a "clinical improvement" in the primary and secondary endpoints, including measures of disease activity and flares.

90

90

STAT

SEPTEMBER 24, 2024

Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom from the Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” Words to live by, yes?

Insurance 89

Insurance 89

Fierce Pharma

SEPTEMBER 24, 2024

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the c | Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.

89

89

Pharmacy Times

SEPTEMBER 24, 2024

Childhood immunization according to schedule can prevent serious illness.

Immunization 129

Immunization Vaccines 129